Shona Fielding1, Marielle Pijnenburg2, Johan C de Jongste2, Katharine C Pike3, Graham Roberts4, Helen Petsky5, Anne B Chang6, Maria Fritsch7, Thomas Frischer7, Stanley Szefler8, Peter Gergen9, Francoise Vermeulen10, Robin Vael11, Steve Turner12. 1. Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland. 2. Department of Paediatric Respiratory Medicine and Allergology, Erasmus MC, Sophia Children's Hospital, Rotterdam, the Netherlands. 3. Clinical and Experimental Science Academic Unit, University of Southampton, Southampton, England; Respiratory Critical Care and Anaesthesia Group, Institute of Child Health, University College London, London, England. 4. Clinical and Experimental Science Academic Unit, University of Southampton, Southampton, England. 5. Department of Respiratory and Sleep Medicine, Lady Cilento Children's Hospital, Queensland University of Technology, Brisbane, Australia. 6. Department of Respiratory and Sleep Medicine, Lady Cilento Children's Hospital, Queensland University of Technology, Brisbane, Australia; Child Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia. 7. Department of General Paediatrics, University Children's Hospital, Vienna, Austria. 8. Breathing Institute, Children's Hospital Colorado, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO. 9. National Institute of Allergy and Infectious Diseases, Bethesda, MD. 10. Pediatric Department, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. 11. Department of Paediatrics, Antwerp University Hospital, Antwerp, Belgium. 12. Department of Child Health, University of Aberdeen, Royal Aberdeen Children's Hospital, Aberdeen, Scotland. Electronic address: s.w.turner@abdn.ac.uk.
Abstract
BACKGROUND: Repeated measurements of spirometry and fractional exhaled nitric oxide (Feno) are recommended as part of the management of childhood asthma, but the evidence base for such recommendations is small. We tested the hypothesis that reducing spirometric indices or increasing Feno will predict poor future asthma outcomes. METHODS: A one-stage individual patient data meta-analysis used data from seven randomized controlled trials in which Feno was used to guide asthma treatment; spirometric indices were also measured. Change in %FEV1 and % change in Feno between baseline and 3 months were related to having poor asthma control and to having an asthma exacerbation between 3 and 6 months after baseline. RESULTS: Data were available from 1,112 children (mean age, 12.6 years; mean %FEV1, 94%). A 10% reduction in %FEV1 between baseline and 3 months was associated with 28% increased odds for asthma exacerbation (95% CI, 3-58) and with 21% increased odds for having poor asthma control (95% CI, 0-45) 6 months after baseline. A 50% increase in Feno between baseline and 3 months was associated with 11% increase in odds for poor asthma control 6 months after baseline (95% CI, 0-16). Baseline Feno and %FEV1 were not related to asthma outcomes at 3 months. CONCLUSIONS: Repeated measurements of %FEV1 that are typically within the "normal" range add to clinical risk assessment of future asthma outcomes in children. The role of repeated Feno measurements is less certain because large changes were associated with small changes in outcome risk.
BACKGROUND: Repeated measurements of spirometry and fractional exhaled nitric oxide (Feno) are recommended as part of the management of childhood asthma, but the evidence base for such recommendations is small. We tested the hypothesis that reducing spirometric indices or increasing Feno will predict poor future asthma outcomes. METHODS: A one-stage individual patient data meta-analysis used data from seven randomized controlled trials in which Feno was used to guide asthma treatment; spirometric indices were also measured. Change in %FEV1 and % change in Feno between baseline and 3 months were related to having poor asthma control and to having an asthma exacerbation between 3 and 6 months after baseline. RESULTS: Data were available from 1,112 children (mean age, 12.6 years; mean %FEV1, 94%). A 10% reduction in %FEV1 between baseline and 3 months was associated with 28% increased odds for asthma exacerbation (95% CI, 3-58) and with 21% increased odds for having poor asthma control (95% CI, 0-45) 6 months after baseline. A 50% increase in Feno between baseline and 3 months was associated with 11% increase in odds for poor asthma control 6 months after baseline (95% CI, 0-16). Baseline Feno and %FEV1 were not related to asthma outcomes at 3 months. CONCLUSIONS: Repeated measurements of %FEV1 that are typically within the "normal" range add to clinical risk assessment of future asthma outcomes in children. The role of repeated Feno measurements is less certain because large changes were associated with small changes in outcome risk.
Authors: Eva J Peirsman; Thierry J Carvelli; Pierre Y Hage; Laurence S Hanssens; Luc Pattyn; Marc M Raes; Kate A Sauer; Françoise Vermeulen; Kristine N Desager Journal: Pediatr Pulmonol Date: 2013-09-04
Authors: Raed A Dweik; Peter B Boggs; Serpil C Erzurum; Charles G Irvin; Margaret W Leigh; Jon O Lundberg; Anna-Carin Olin; Alan L Plummer; D Robin Taylor Journal: Am J Respir Crit Care Med Date: 2011-09-01 Impact factor: 21.405
Authors: Mariëlle W Pijnenburg; E Marije Bakker; Wim C Hop; Johan C De Jongste Journal: Am J Respir Crit Care Med Date: 2005-06-23 Impact factor: 21.405
Authors: Philip H Quanjer; Sanja Stanojevic; Tim J Cole; Xaver Baur; Graham L Hall; Bruce H Culver; Paul L Enright; John L Hankinson; Mary S M Ip; Jinping Zheng; Janet Stocks Journal: Eur Respir J Date: 2012-06-27 Impact factor: 16.671
Authors: Leonard B Bacharier; Robert C Strunk; David Mauger; Deborah White; Robert F Lemanske; Christine A Sorkness Journal: Am J Respir Crit Care Med Date: 2004-06-01 Impact factor: 21.405
Authors: Andrew J Collaro; Anne B Chang; Julie M Marchant; Ian B Masters; Leanne T Rodwell; Allan J Takken; Margaret S McElrea Journal: Lung Date: 2020-02-20 Impact factor: 2.584
Authors: Shona Fielding; Marielle Pijnenburg; Johan C de Jongste; Katharine C Pike; Graham Roberts; Helen Petsky; Anne B Chang; Maria Fritsch; Thomas Frischer; Stanley Szefler; Peter Gergen; Francoise Vermeulen; Robin Vael; Steve Turner Journal: Chest Date: 2019-06 Impact factor: 9.410
Authors: Susanne J H Vijverberg; Paul Brinkman; Niels W P Rutjes; Anke H Maitland-van der Zee Journal: Curr Opin Pulm Med Date: 2020-01 Impact factor: 2.868
Authors: S Turner; S C Cotton; C D Emele; R Thomas; S Fielding; E A Gaillard; J C de Jongste; H Morgan; A R Neilson; J Norrie; M Pijnenburg; D Price; M Thomas Journal: Trials Date: 2019-10-04 Impact factor: 2.279